16. Curtin, K., Fleckenstein, A. E., Robison, R. J., Crookston, M. J., Smith, K. R., & Hanson, G. R. (2015). Methamphetamine/amphetamine abuse and risk of Parkinson’s disease in Utah: a population-based assessment. Drug and Alcohol Dependence, 146, 30–38. http://doi.org/10.1016/j.drugalcdep.2014.10.027
17. Deuschl, G., Papengut, F., & Hellriegel, H. (2012). The phenomenology of parkinsonian tremor. Parkinsonism & related disorders, 18, S87-S89.
18. Dickson, D. W. (2012). Parkinson’s disease and parkinsonism: neuropathology. Cold Spring Harbor perspectives in medicine, 2(8), a009258.
19. Duval, C., Daneault, J. F., Hutchison, W. D., & Sadikot, A. F. (2016). A brain network model explaining tremor in Parkinson's disease. Neurobiology of disease, 85, 49-59.
20. Dzamko, N., & Halliday, G. M. (2012). An emerging role for LRRK2 in the immune system.
21. Eriksson, A.-K., Löfving, S., Callaghan, R. C., & Allebeck, P. (2013). Alcohol use disorders and risk of Parkinson’s disease: findings from a Swedish national cohort study 1972–2008. BMC Neurology, 13, 190. http://doi.org/10.1186/1471-2377-13-190
22. Gibrat, C., Saint‐Pierre, M., Bousquet, M., Lévesque, D., Rouillard, C., & Cicchetti, F. (2009). Differences between subacute and chronic MPTP mice models: investigation of dopaminergic neuronal degeneration and α‐synuclein inclusions. Journal of neurochemistry, 109(5), 1469-1482.
23. Goetz, C. G. (2011). The History of Parkinson’s Disease: Early Clinical Descriptions and Neurological Therapies. Cold Spring Harbor Perspectives in Medicine:, 1(1), a008862. http://doi.org/10.1101/cshperspect.a008862
24. Hagell, P., & Brundin, L. (2009). Towards an understanding of fatigue in Parkinson’s disease. Journal of Neurology, Neurosurgery & Psychiatry.
25. Hariz, M. (2012). Twenty‐five years of deep brain stimulation: Celebrations and apprehensions. Movement Disorders, 27(7), 930-933.
26. Hickey, P., & Stacy, M. (2011). Available and emerging treatments for Parkinson’s disease: a review. Drug Design, Development and Therapy, 5, 241–254. http://doi.org/10.2147/DDDT.S11836
27. INEGI. (2015). Encuesta intercensal. Recuperado de http://www.beta.inegi.org.mx/proyectos/enchogares/especiales/intercensal/
28. Inzelberg, R., Samuels, Y., Azizi, E., Qutob, N., Inzelberg, L., Domany, E., … Friedman, E. (2016). Parkinson disease (PARK) genes are somatically mutated in cutaneous melanoma. Neurology: Genetics, 2(3), e70. http://doi.org/10.1212/NXG.0000000000000070
29. Ishihara, L. S., Cheesbrough, A., Brayne, C., & Schrag, A. (2007). Estimated life expectancy of Parkinson’s patients compared with the UK population. Journal of Neurology, Neurosurgery, and Psychiatry, 78(12), 1304–1309. http://doi.org/10.1136/jnnp.2006.100107
30. Ivey, F. M., Katzel, L. I., Sorkin, J. D., Macko, R. F., & Shulman, L. M. (2012). The Unified Parkinson’s Disease Rating Scale as a predictor of peak aerobic capacity and ambulatory function. Journal of Rehabilitation Research and Development, 49(8), 1269–1276.
31. Jankovic, J. (2008). Parkinson’s disease: clinical features and diagnosis. Journal of Neurology, Neurosurgery & Psychiatry, 79(4), 368-376.
32. Kalia, L.V., Lang, A, E, (2015). Parkinson’s disease. Lancet. 386(9996):896–912
33. Karimi, M., Golchin, N., Tabbal, S. D., Hershey, T., Videen, T. O., Wu, J., ... & Mink, J. W. (2008). Subthalamic nucleus stimulation-induced regional blood flow responses correlate with improvement of motor signs in Parkinson disease. Brain, 2710-2719.
34. Keener, A. M., & Bordelon, Y. M. (2016). Parkinsonism. In Seminars in neurology (Vol. 36, No. 04, pp. 330-334). Thieme Medical Publishers.
35. Klein, C., & Westenberger, A. (2012). Genetics of Parkinson’s Disease. Cold Spring Harbor Perspectives in Medicine, 2(1), a008888. http://doi.org/10.1101/cshperspect.a008888
36. Kordower, J. H. (2015). Gene Therapy for Parkinson’s Disease: Still a Hot Topic? Neuropsychopharmacology, 40(1), 255–256. http://doi.org/10.1038/npp.2014.235
37. Krawczyk, R., Klejbor, I., Turlejski, K., Ludkiewicz, B., & Moryś, J. (2015). Organisation of the dopamine neuronal subsets within midbrain of the Pygmy Acrobat. Folia Morphologica
38. Kriks, S., Shim, J. W., Piao, J., Ganat, Y. M., Wakeman, D. R., Xie, Z., ... & Yang, L. (2011). Dopamine neurons derived from human ES cells efficiently engraft in animal models of Parkinson/'s disease. Nature, 480(7378), 547-551.
39. Kumar, D. R., Aslinia, F., Yale, S. H., & Mazza, J. J. (2011). Jean-Martin Charcot: The Father of Neurology. Clinical Medicine & Research, 9(1), 46–49. http://doi.org/10.3121/cmr.2009.883
40. Langston, J. W. (2017). The MPTP Story. Journal of Parkinson’s Disease, 7(Suppl 1), S11–S22. http://doi.org/10.3233/JPD-179006
41. Lauzé, M., Daneault, J.-F., & Duval, C. (2016). The Effects of Physical Activity in Parkinson’s Disease: A Review. Journal of Parkinson’s Disease, 6(4), 685–698. http://doi.org/10.3233/JPD-160790
42. Lees AJ, Hardy J, Revesz T. (2009). Pakinson´s disease. Lancet. 373(9680):2055-66. doi: 10.1016/S0140-6736(09)60492-X.
43. Lehéricy, S., Bardinet, E., Poupon, C., Vidailhet, M., & François, C. (2014). 7 Tesla magnetic resonance imaging: a closer look at substantia nigra anatomy in Parkinson's disease. Movement Disorders, 29(13), 1574-1581.
44. Lim, K. L., & Zhang, C. W. (2013). Molecular events underlying Parkinson’s disease–an interwoven tapestry. Frontiers in neurology, 4.
45. Lin, M. K., & Farrer, M. J. (2014). Genetics and genomics of Parkinson’s disease. Genome Medicine, 6(6), 48. http://doi.org/10.1186/gm566
46. Lugo, G. (2017). En México, alta incidencia de Parkinson en menores de 40 años | gaceta Digital UNAM. Gaceta.unam.mx. Recuperado 10 noviembre 2017 de http://www.gaceta.unam.mx/20150416/en-mexico-alta-incidencia-de-parkinson-en-menores-de-40-anos/
47. Macedo-Márquez, A. (2012). La producción de especies reactivas de oxígeno (EROs) en las mitocondrias de Saccharomyces cerevisiae. TIP. Revista especializada en ciencias químico-biológicas, 15(2), 97-103.
48. Magrinelli, F., Picelli, A., Tocco, P., Federico, A., Roncari, L., Smania, N., … Tamburin, S. (2016). Pathophysiology of Motor Dysfunction in Parkinson’s Disease as the Rationale for Drug Treatment and Rehabilitation. Parkinson’s Disease, 2016, 9832839. http://doi.org/10.1155/2016/9832839
11